ES2014593A6 - Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1. - Google Patents
Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1.Info
- Publication number
- ES2014593A6 ES2014593A6 ES8901125A ES8901125A ES2014593A6 ES 2014593 A6 ES2014593 A6 ES 2014593A6 ES 8901125 A ES8901125 A ES 8901125A ES 8901125 A ES8901125 A ES 8901125A ES 2014593 A6 ES2014593 A6 ES 2014593A6
- Authority
- ES
- Spain
- Prior art keywords
- fragments
- expression
- protein
- secreted
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100030886 Complement receptor type 1 Human genes 0.000 title abstract 2
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Joining Of Building Structures In Genera (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
METODO PARA PREPARAR UN VECTOR DE ACIDO NUCLEICO QUE CODIFICA UNA PROTEINA DE CR1. CONSISTE EN INTRODUCIR EN UNA CELULA UN VECTOR DE ACIDO NUCLEICO QUE COMPRENDE LA SECUENCIA DE NUCLEOTIDOS DEL GEN DEL RECEPTOR C3B/C4B (CR1), Y PROPAGAR EL VECTOR DE ACIDO NUCLEICO MEDIANTE PROPAGACION DE LA CELULA, ELIGIENDOSE ESTA PREFERIBLAMENTE ENTRE BACTERIAS Y CELULAS DE MAMIFEROS. EL INVENTO PERMITE OBTENER TAMBIEN SECUENCIAS DE ACIDOS NUCLEICOS DE CR1 Y FRAGMENTOS DE LAS MISMAS QUE CONTIENEN 70 NUCLEOTIDOS, ASI COMO SUS PEPTIDOS O PROTEINAS CODIFICADOS QUE CONTIENEN 24 AMINOACIDOS, PROPORCIONANDOSE ADEMAS LA EXPRESION DE LA PROTEINA DE CR1 Y SUS FRAGMENTOS. LOS PRODUCTOS OBTENIDOS SON UTILES EN DIAGNOSTICOS Y TERAPIA DE DIVERSAS AFECCIONES DEL SISTEMA INMUNE Y ENFERMEDADES INFLAMATORIAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17653288A | 1988-04-01 | 1988-04-01 | |
US41274589A | 1989-09-26 | 1989-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2014593A6 true ES2014593A6 (es) | 1990-07-16 |
Family
ID=26872337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES8901125A Expired - Lifetime ES2014593A6 (es) | 1988-04-01 | 1989-03-31 | Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0411031B1 (es) |
JP (1) | JP3484189B2 (es) |
CN (2) | CN1092712C (es) |
AT (1) | ATE240973T1 (es) |
CA (2) | CA1340866C (es) |
DE (1) | DE68929466T2 (es) |
DK (1) | DK175699B1 (es) |
ES (1) | ES2014593A6 (es) |
FI (2) | FI106316B (es) |
IL (1) | IL89790A (es) |
NO (1) | NO315944B1 (es) |
SG (1) | SG52789A1 (es) |
WO (1) | WO1989009220A1 (es) |
ZA (2) | ZA892397B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5426029A (en) * | 1986-03-31 | 1995-06-20 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using leukocyte surface antigens |
US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
US6482404B1 (en) | 1989-10-12 | 2002-11-19 | David James White | Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor |
ES2060561T3 (es) | 1989-10-12 | 1996-08-01 | Imutran Ltd | Material biologico modificado. |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6458360B1 (en) * | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
JP4236698B2 (ja) * | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー | 宿主細胞でのpaceの発現およびその使用法 |
CA2097825A1 (en) * | 1990-12-06 | 1992-06-07 | Henry C. Marsh, Jr. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
EP1413587A2 (en) * | 1991-05-03 | 2004-04-28 | Washington University | Modified complement system regulator |
DE69328098T2 (de) * | 1992-06-24 | 2000-08-24 | Adprotech Plc | Lösliche derivate des complement type-rezeptors (cr1) |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
ATE223230T1 (de) * | 1993-02-12 | 2002-09-15 | Avant Immunotherapeutics Inc | Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1 |
BR9708387A (pt) | 1996-03-28 | 2000-01-04 | Genitrix Llc | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
GB9706950D0 (en) * | 1997-04-05 | 1997-05-21 | Chernajovsky Yuti | Immune modulation by polypeptides related to CR1 |
AU5317499A (en) * | 1998-07-24 | 2000-02-14 | Uab Research Foundation | Genetic polymorphism in a complement receptor |
US6664052B1 (en) | 1998-07-24 | 2003-12-16 | The Uab Research Foundation | Genetic polymorphism in a complement receptor |
GB9905503D0 (en) | 1999-03-10 | 1999-05-05 | Adprotech Plc | Novel compound formulations and methods of delivery |
EP1738763A1 (en) | 2005-06-30 | 2007-01-03 | AVANT Immunotherapeutics, Inc. | Use of complement inhibitory proteins to treat spinal cord injury |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
WO2010047793A2 (en) | 2008-10-21 | 2010-04-29 | The General Hospital Corporation | Cell transplantation |
US10184110B2 (en) | 2010-08-06 | 2019-01-22 | The General Hospital Corporation | System and apparatus for cell treatment |
CN103237557A (zh) | 2010-09-15 | 2013-08-07 | 赛尔戴克斯治疗公司 | 用可溶性I型补体受体(sCR1)治疗慢性肾病 |
BR112013010098A2 (pt) | 2010-10-27 | 2017-06-13 | Celldex Therapeutics Inc | método para melhorar a função de transplante usando um receptor do complemento solúvel tipo i (scr1) |
EP3095876A1 (en) | 2010-11-02 | 2016-11-23 | Kypha, Inc. | Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
CN102702339B (zh) * | 2011-05-24 | 2013-10-30 | 华南师范大学 | 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用 |
BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
CN104293836A (zh) * | 2014-06-24 | 2015-01-21 | 长沙赢润生物技术有限公司 | 一种免疫复合物吸附细胞的制作方法 |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
EP3760645A1 (en) * | 2019-07-02 | 2021-01-06 | imusyn GmbH & Co. KG | Analysis for blood group antigen dacy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60192948A (ja) * | 1984-03-14 | 1985-10-01 | Fuji Photo Film Co Ltd | 湿し水不要ネガ型感光性平版印刷版および製版方法 |
US4672044A (en) * | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
-
1989
- 1989-03-29 IL IL8979089A patent/IL89790A/en active IP Right Grant
- 1989-03-31 DE DE68929466T patent/DE68929466T2/de not_active Expired - Fee Related
- 1989-03-31 JP JP50500089A patent/JP3484189B2/ja not_active Expired - Fee Related
- 1989-03-31 ES ES8901125A patent/ES2014593A6/es not_active Expired - Lifetime
- 1989-03-31 EP EP89905249A patent/EP0411031B1/en not_active Expired - Lifetime
- 1989-03-31 WO PCT/US1989/001358 patent/WO1989009220A1/en active IP Right Grant
- 1989-03-31 SG SG1996009545A patent/SG52789A1/en unknown
- 1989-03-31 AT AT89905249T patent/ATE240973T1/de not_active IP Right Cessation
- 1989-03-31 CA CA000595389A patent/CA1340866C/en not_active Expired - Fee Related
- 1989-03-31 ZA ZA892397A patent/ZA892397B/xx unknown
- 1989-03-31 CA CA000617127A patent/CA1341443C/en not_active Expired - Fee Related
- 1989-04-01 CN CN89101990A patent/CN1092712C/zh not_active Expired - Fee Related
-
1990
- 1990-09-26 ZA ZA907693A patent/ZA907693B/xx unknown
- 1990-09-26 CN CN90108145A patent/CN1053924C/zh not_active Expired - Fee Related
- 1990-09-28 DK DK199002348A patent/DK175699B1/da not_active IP Right Cessation
- 1990-10-01 FI FI904842A patent/FI106316B/fi active IP Right Grant
-
2000
- 2000-02-18 NO NO20000827A patent/NO315944B1/no not_active IP Right Cessation
- 2000-11-16 FI FI20002515A patent/FI115528B/fi active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP3484189B2 (ja) | 2004-01-06 |
IL89790A (en) | 2002-05-23 |
SG52789A1 (en) | 1998-09-28 |
WO1989009220A1 (en) | 1989-10-05 |
CN1036987A (zh) | 1989-11-08 |
NO20000827D0 (no) | 2000-02-18 |
NO20000827L (no) | 1990-11-09 |
AU3539489A (en) | 1989-10-16 |
IL89790A0 (en) | 1989-09-28 |
ZA907693B (en) | 1992-05-27 |
CN1053924C (zh) | 2000-06-28 |
CN1053265A (zh) | 1991-07-24 |
CN1092712C (zh) | 2002-10-16 |
ZA892397B (en) | 1989-11-29 |
DE68929466D1 (de) | 2003-06-26 |
NO315944B1 (no) | 2003-11-17 |
EP0411031A1 (en) | 1991-02-06 |
DK234890A (da) | 1990-11-30 |
DE68929466T2 (de) | 2004-04-01 |
FI20002515A (fi) | 2000-11-16 |
EP0411031A4 (en) | 1992-02-05 |
ATE240973T1 (de) | 2003-06-15 |
CA1340866C (en) | 1999-12-28 |
DK234890D0 (da) | 1990-09-28 |
DK175699B1 (da) | 2005-01-24 |
FI904842A0 (fi) | 1990-10-01 |
AU647371B2 (en) | 1994-03-24 |
FI115528B (fi) | 2005-05-31 |
CA1341443C (en) | 2003-10-07 |
JPH04501502A (ja) | 1992-03-19 |
EP0411031B1 (en) | 2003-05-21 |
FI106316B (fi) | 2001-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0502892A4 (en) | The human c3b/c4b receptor (cr1) | |
ES2014593A6 (es) | Un metodo para preparar un vector de acido nucleico que codifica una proteina de cr1. | |
Seidman et al. | The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone | |
US5401651A (en) | DNA encoding ENA-78, a neutrophil activating factor | |
Reeves et al. | Molecular cloning of a functional bovine interleukin 2 cDNA. | |
KR970705405A (ko) | 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides) | |
HUT77578A (hu) | A 10-es számú fibroblaszt növekedési faktor (FGF-10) | |
Green et al. | Identification and characterization of PF4varl, a human gene variant of platelet factor 4 | |
NZ503235A (en) | Amino-terminally truncated RANTES as chemokine antagonists | |
CA2062969A1 (en) | Recombinantly produced human membrane cofactor protein (mcp) | |
MX9203654A (es) | Purificacion, clonacion y caracterizacion del gen para la interleucina i. | |
CA2202519A1 (en) | Cloning, expression and characterization of a new form of phosphatidylinositol-3-kinase | |
CA2342770A1 (en) | Ly6h gene | |
EP0913470A3 (en) | The human C3b/C4b receptor (CR1) | |
JP2002519016A (ja) | 疎水性ドメインを有するヒト蛋白質とそれをコードするdna | |
KR930701475A (ko) | 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법 | |
EP0353516B1 (en) | A method for the preparation of recombinant human beta interleukin-1 in the homogeneous form | |
EP0308424A1 (en) | A novel protein, neuroleukin | |
EP0341100A2 (en) | DNA coding for thymosin and TNF | |
KR20010030984A (ko) | 폴리펩티드, 그 폴리펩티드를 암호화하는 cDNA 및이들의 용도 | |
WO1998004692A3 (en) | Human neuronatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD1A | Patent lapsed |
Effective date: 20080401 |